In Group 3, in a similar manner, 3 patients will be enrolled and administered a single intravitreal injection of TLC399 (ProDex), i.e., 0.6 mg DSP with 50 mM PL (50 µL) on Day 0. After the intravitreal injection, each patient will be observed for 4 weeks for Dose Limiting Toxicities (DLTs). If 1 of 3 patients develops Dose Limiting Toxicities (DLTs), the cohort will be expanded to a maximum of 6 patients (another 3 patients added subsequently). If no patient experiences a Dose Limiting Toxicity (DLT) or exactly 1 of the 6 patients experiences Dose Limiting Toxicities (DLTs), then the study will proceed to Part 2 with all 3 dose groups, Groups 1, 2, and 3. If more than 1 patient out of the 6 develops Dose Limiting Toxicities (DLTs), then the dose of Group 2 will be the Dose Limiting Toxicity (DLT). Part 2 of the study will commence with the 2 dose groups, Groups 1 and 2.